Johnson & Johnson Covid-19 Vaccine Batch Fails Quality Check
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A batch of Johnson & Johnson's Covid-19 vaccine failed quality standards and can't be used, the drug giant said. The drugmaker didn't say how many doses were lost, and it wasn't clear how the problem would impact future deliveries. A vaccine ingredient made by Emergent BioSolutions did not meet quality standards, J&J said.

J&J said the Emergent BioSolutions factory involved had not yet been approved by the U.S. Food and Drug Administration to make part of the vaccine. Emergent, which has been producing bulk drug substance at one of its factories in Baltimore, declined to comment. J&J had pledged to provide 20 million doses of its vaccine to the U.S. government by the end of March, and 80 million more doses by the end of May.

Its statement on the manufacturing problem said it was still planning to deliver 100 million doses by the end of June and was aiming to deliver those doses by the end of May. President Joe Biden has pledged to have enough vaccines for all U.S. adults by the end of May. The U.S. government has ordered enough two-dose shots from Pfizer and Moderna to vaccinate 200 million people to be delivered by late May, plus the 100 million shots from J&J.

A federal official said Wednesday evening the administration's goal can be met without additional J&J doses. A J&J spokesman said that J&J met the end-of-March goal, but did not respond to questions about whether the Emergent plant had been cleared by FDA.

Source:
https://health.economictimes.indiatimes.com/news/pharma/johnson-johnson-covid-19-vaccine-batch-fails-quality-check/81816512
6 shares
Like
Comment
Share